Sabyasachy Mistry | Molecular Mechanisms Signaling | Best Researcher Award

Posted on by sciencefather

Dr. Sabyasachy Mistry | Molecular Mechanisms Signaling | Best Researcher Award

Dr. Sabyasachy Mistry , US FDA , United States

Sabyasachy (Babu) Mistry is a highly skilled bioanalyst with over sixteen years of experience in analytical chemistry, organic synthesis, and bioanalytical method development. He is currently working at the US Food and Drug Administration (FDA) in Silver Spring, MD. Mistry has a broad expertise that spans liquid chromatography-mass spectrometry (LC-MS/MS), enzyme-linked immunosorbent assay (ELISA), nuclear magnetic resonance (NMR), and various organic chemistry techniques. With strong communication and problem-solving skills, Mistry excels both as a team member and independent researcher. He has contributed to multiple scientific publications, focusing on pharmacokinetics, drug discovery, and regulatory practices, in addition to mentoring students and offering leadership roles in academic settings.

Publication Profile: 

Scopus

Strengths for the Award:

Sabyasachy (Babu) Mistry’s distinguished experience in analytical and bioanalytical chemistry makes him a strong contender for the Research for Best Researcher Award. With over sixteen years of experience, his expertise spans liquid chromatography-mass spectrometry (LC-MS/MS), enzyme-linked immunosorbent assays (ELISA), and computational chemistry, among others. His work in drug solubility and pharmacokinetics, particularly his contributions to hERG assays, is highly relevant to regulatory sciences. Mistry’s capacity to bridge scientific inquiry with FDA regulations ensures his research not only advances scientific understanding but also directly supports regulatory science. His well-documented research, combined with leadership roles and multiple awards, reinforces his research excellence.

Areas for Improvements:


While Mistry’s expertise is extensive, further expansion into collaborative, cross-disciplinary projects could further enrich his body of work. Engaging more in international research initiatives could lead to innovative research outcomes and foster broader scientific networks.

Education:

Sabyasachy Mistry holds a Ph.D. in Analytical Chemistry from Purdue University, where he conducted research under the guidance of Professor Paul G. Wenthold. His dissertation focused on mass spectrometric detection of indophenols for phenol analysis. Prior to this, Mistry completed his M.S. in Organic Chemistry from the University of Dhaka in Bangladesh, where he worked with Professor Nilufar Nahar. His solid educational foundation, combined with his hands-on research experience, has provided him with expertise in a wide range of scientific disciplines, including analytical chemistry, organic synthesis, and bioanalytical methods. Furthermore, Mistry completed the CERSI Immersion Course in Drug Discovery, Drug Development, and Regulation at the UCSF-Stanford Center of Excellence in Regulatory Science and Innovation, strengthening his knowledge in FDA regulations and drug development processes.

Experience:

Mistry’s extensive professional experience spans over a decade in both academic and regulatory environments. Since 2020, he has been serving as a Bio-analyst at the US Food and Drug Administration (FDA), where he applies his expertise in analytical chemistry to support drug discovery and regulatory science. At Purdue University, Mistry worked as a Teaching Assistant (TA) and Head TA in the Department of Chemistry from 2014 to 2020, fostering the growth of new scientists while also contributing to research. His responsibilities included conducting experiments, guiding graduate students, and presenting research findings. Mistry’s work involves advanced techniques such as LC-MS/MS, HPLC, NMR, and computational chemistry tools like Gaussian and Q-Chem. His cross-disciplinary research has contributed to the scientific understanding of pharmacokinetics, drug solubility, and enzyme activity, aligning with regulatory practices in drug approval processes.

Awards and Honors:

Sabyasachy Mistry has been recognized for his outstanding contributions to analytical and bioanalytical chemistry. He was awarded the Graduate Student Travel Award at the 67th ASMS Conference on Mass Spectrometry and Allied Topics in June 2019 in Atlanta, GA. Additionally, Mistry received multiple Travel Scholarships for his student work at the ASMS conferences from 2016 to 2018, showcasing his dedication to advancing scientific knowledge. His role as a volunteer and mentor further exemplifies his leadership within the academic community. These awards highlight his exceptional skills in mass spectrometry and analytical techniques, further solidifying his expertise in the field of chemical research. Mistry’s ability to present complex scientific data and his contributions to regulatory science have garnered recognition from peers and industry professionals alike.

Research Focus:

Sabyasachy Mistry’s research focuses on bioanalytical chemistry, pharmacokinetics, and regulatory science, particularly in drug discovery and development. His work involves the application of advanced techniques such as LC-MS/MS, ELISA, HPLC, and mass spectrometry to investigate drug interactions, solubility, and bioavailability. Mistry’s research also extends to the computational aspects of chemistry, using density functional theory (DFT) calculations to predict reaction profiles and optimize molecular interactions. A key area of interest for Mistry is studying the effects of drug formulations on biological systems, particularly through hERG assays to assess drug safety and efficacy. His work aligns with FDA regulations and contributes to improving drug regulatory processes. Additionally, Mistry has a strong background in organic chemistry, working on the synthesis and modification of small organic molecules. This combination of experimental and computational chemistry makes his research multifaceted, bridging the gap between scientific discovery and regulatory implementation.

Publications Top Notes:

  1. Determination of Lopinavir and Ritonavir in hERG solution to Support In Vitro hERG Block Potency Assessment Using LC-MS/MS: The Challenge of Poor Drug Solubility 📑
  2. Evaluation of a Sequential Antibiotic Treatment Regimen of Ampicillin, Ciprofloxacin, and Fosfomycin against Escherichia coli CFT073 in the Hollow Fiber Infection Model Compared with Simultaneous Combination Treatment 💊
  3. Determination of Five Positive Control Drugs in hERG External Solution (Buffer) by LC-MS/MS to Support In Vitro hERG Assay as Recommended by ICH S7B ⚖️
  4. Probing the Pyrolysis of Guaiacol and Dimethoxybenzenes Using Collision-Induced Dissociation Charge-Remote Fragmentation Mass Spectrometry 🔬
  5. Investigation of the Substituent Effects of the Azide Functional Group Using the Gas-Phase Acidities of 3- and 4-Azidophenols 📚
  6. Mass Spectrometric Detection of the Gibbs Reaction for Phenol Analysis 🔍
  7. Participation of C-H Protons in the Dissociation of a Proton Deficient Dipeptide 💡
  8. The HIVToolbox 2 Web System Integrates Sequence, Structure, Function and Mutation Analysis 🧬
  9. The Geogenomic Mutational Atlas of Pathogens (GoMAP) Web System 🌍
  10. Effect of Sodium Bicarbonate on the Mechanical and Degradation Properties of Short Jute Fiber Reinforced Polypropylene Composite by Extrusion Technique 🔧

Conclusion:

Sabyasachy Mistry has demonstrated exceptional scientific acumen and practical contributions in the field of bioanalytical chemistry. His expertise and leadership in various research domains position him as an excellent candidate for the Research for Best Researcher Award. His continued work on drug discovery and regulatory science will likely result in even greater contributions to both the scientific and regulatory communities.

 

 

 

Gonca Çelik | Developmental Cell Biology | Best Researcher Award

Posted on by sciencefather

Assoc. Prof. Dr. Gonca Çelik | Developmental Cell Biology | Best Researcher Award

Assoc. Prof. Dr. Gonca Çelik , Karadeniz Technical University , Turkey

Assoc. Prof. Dr. Gonca Çelik, born on April 18, 1984, is a distinguished academic with an extensive background in chemistry, particularly in organic chemistry. She earned her bachelor’s degree in Chemistry Teaching from Karadeniz Technical University (KTU) in 2008. Later, she pursued a doctorate in Chemistry, specializing in Organic Chemistry, from KTU, completing her Ph.D. in 2017. With an h-index of 12, she has made significant contributions to scientific research, including 38 publications in SCI-Expanded indexed journals. Dr. Çelik is also recognized for her involvement in various research projects, particularly in enzyme inhibition, molecular docking studies, and the synthesis of bioactive compounds. Fluent in both Turkish and English, she actively collaborates internationally and has authored several impactful publications related to drug development and the synthesis of biologically active compounds, contributing to fields such as medicinal chemistry and biochemistry.

Publication Profile:

Scopus

Strengths for the Award:

Assoc. Prof. Dr. Gonca Çelik is a highly accomplished researcher with a strong background in organic chemistry, particularly in drug development and biological evaluations. Her significant contributions to the field are reflected in her 38 publications in SCI-Expanded indexed journals. She has demonstrated expertise in synthesizing bioactive compounds, investigating their biological activities, and applying molecular modeling techniques, including molecular docking and ADMET studies. Her work on the synthesis of flavonol derivatives, which are potential inhibitors of SARS-CoV-2, underscores her impact on global health research. Dr. Çelik has also been an active participant in multiple national and international research projects, including Tubitak-funded projects, focusing on enzyme inhibition and molecular modeling for disease treatment. Her leadership in scientific research, combined with a solid academic background, positions her as a valuable contributor to scientific advancements.

Areas for Improvement:

While Dr. Çelik’s research is impressive, there is room for greater visibility and dissemination of her findings to broader interdisciplinary audiences. Increased collaboration with researchers from other scientific fields, such as pharmacology and clinical medicine, could enhance the real-world application of her work, particularly in the development of drug therapies. Expanding her research focus to include more clinical trials or translational research could help bridge the gap between laboratory findings and practical medical applications. Additionally, increasing her involvement in scientific outreach or mentorship programs could further contribute to the development of the next generation of researchers in chemistry and pharmacology.

Education:

Dr. Gonca Çelik’s educational journey began with a Bachelor’s degree in Chemistry Teaching from Karadeniz Technical University (KTU) in 2008. She then pursued postgraduate studies, enrolling directly in the doctoral program in Chemistry at KTU, where she specialized in Organic Chemistry, completing her Ph.D. in 2017. Her doctoral research focused on developing bioactive organic compounds with potential therapeutic applications. Dr. Çelik has also gained international exposure during her Master’s studies, spending time at Clausthal University of Technology in Germany in 2014, which broadened her academic perspective and research experience. Over the years, her educational background and research expertise have provided a solid foundation for her ongoing contributions to the field of organic chemistry, particularly in medicinal chemistry, enzyme inhibition, and molecular docking studies. This strong academic base supports her continued success as an academic and researcher in the field of chemistry.

Experience:

Dr. Gonca Çelik’s academic and professional journey spans over a decade. She began her career as a Research Assistant at Karadeniz Technical University (KTU) in 2010, where she worked until 2017. During her time at KTU, she contributed to several research projects in the field of chemistry, including organic synthesis and biological evaluation of compounds. Her academic work has led her to publish multiple papers in international and national journals. In 2014, she expanded her research horizons by spending time as a Master Student at Clausthal University of Technology in Germany, further strengthening her academic profile. Dr. Çelik has also been involved in various Tubitak and KTU-supported research projects, particularly focusing on enzyme inhibition, molecular docking, and bioactive compound synthesis. She has held roles in multiple projects, such as the synthesis of flavonol derivatives for drug development and the study of antimicrobial and anticancer properties of organic compounds.

Research Focus:

Dr. Gonca Çelik’s primary research interests lie in the field of organic chemistry, with a particular focus on bioactive compound synthesis, enzyme inhibition, and molecular docking studies. Her research aims to discover and develop novel organic molecules with potential therapeutic applications, especially in drug development for diseases such as COVID-19. She has worked extensively on synthesizing flavonol derivatives and other bioactive compounds, investigating their enzyme inhibition efficiencies and biological activities. Dr. Çelik’s work in molecular modeling and computational studies (e.g., ADMET and molecular docking) complements her experimental research, helping to predict the behavior of synthesized compounds at the molecular level. Her research has contributed to the development of potential inhibitors for viruses and other diseases, highlighting her interdisciplinary approach that bridges chemistry and pharmacology. She has been involved in several national and international projects, contributing to the scientific community through her publications and innovative research efforts.

Publications Top Notes:

  1. Synthesis, Biological Evaluation and Molecular Docking Studies of Flavonol-3-O-β-D-glycoside as a Potential Inhibitor of SARS-CoV-2 Main Protease (3CLpro) in Drug Development for COVID-19 🧬💊
  2. Synthesis, structural, spectroscopic (NMR, FT-IR and UV–Vis), NLO, in silico (ADMET and molecular docking) and DFT investigations of a flavonol derivative 2-(4-chlorophenyl)-7-fluoro-3-hydroxy-4H-chromen-4-one 🧪🔬
  3. Antimicrobial, cytotoxic, antiviral effects, and spectroscopic characterization of metabolites produced by fusarium oxysporum yp9b 🦠💉
  4. Biological activity, and volatile and phenolic compounds from five Lamiaceae species 🌱🧴
  5. Synthesis, spectroscopic, and photophysicochemical behavior of Zn(II) and Mg(II) phthalocyanine–chalcone conjugates ⚙️🧑‍🔬
  6. New chalcone-3-O-glycoside derivatives: Synthesis and characterization 🧪🔬
  7. Synthesis and characterization of some new pyrazolines and their inhibitory potencies against carbonic anhydrases 🧫💥

Conclusion:

Dr. Gonca Çelik’s academic achievements, extensive publication record, and leadership in research make her a strong contender for the Best Researcher Award. Her work has made substantial contributions to drug development, specifically in the context of COVID-19 treatment, enzyme inhibition, and molecular modeling. With a solid foundation in chemistry and a forward-looking approach to interdisciplinary research, she continues to push the boundaries of scientific knowledge. Enhancing her outreach efforts and fostering collaborations with clinical researchers will further amplify the impact of her work on global health. Therefore, Dr. Çelik’s research excellence, combined with her potential for future advancements, makes her a deserving candidate for the Best Researcher Award.